Trusted Resources: Education
Scientific literature and patient education texts
A Caregiver’s Guide to Zolgensma
source: Novartis Gene Therapies, Inc
ZOLGENSMA® (onasemnogene abeparvovec-xioi) is a prescription gene therapy used to treat children less than 2 years old with spinal muscular atrophy (SMA). ZOLGENSMA is given as a one-time infusion into a vein. ZOLGENSMA was not evaluated in patients with advanced SMA.
Important Safety Information
ZOLGENSMA can increase liver enzyme levels and cause acute serious liver injury or acute liver failure. Patients will receive an oral corticosteroid before and after infusion with ZOLGENSMA and will undergo regular blood tests to monitor liver function. Contact the patient’s doctor immediately if the patient’s skin and/or whites of the eyes appear yellowish, if the patient misses a dose of corticosteroid or vomits it up, or if the patient experiences a decrease in alertness.
Combination Therapy With Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type ISpinal muscular atrophy (SMA) is a neuro...
Expert Recommendations and Clinical Considerations in the Use of Onasemnogene Abeparvovec Gene Therapy for Spinal Mu...Spinal muscular atrophy (SMA) is an auto...
Recombinant Adeno-Associated Virus Serotype 9 Gene Therapy in Spinal Muscular AtrophySpinal muscular atrophy (SMA) is an auto...
Patient of the Month: GiannaAfter noticing that her daughter was una...
Spinal Muscular Atrophy Fact SheetWhat is spinal muscular atrophy?Spinal m...
Why Some Drugs Cost $2.1 Million per Dose and how one Company Plans to Change ThisWith a cost of $2.1 million for a one-do...
New Treatment Can Help Fresno Infant With Rare Genetic DisorderA Fresno family is holding onto hope aft...